SCHEMBL2815787

SCHEMBL2815787

CNc1nc2ccccc2n2c(CCc3ccccc3)cnc12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.50
IKBKB O14920 5/20 0.46
CHUK O15111 3/20 0.46
TOP2A P11388 1/20 0.44
ADORA1 P30542 2/20 0.44
MAPK8 P45983 2/20 0.44
ADORA3 P0DMS8 2/20 0.42
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
BRD4 O60885 1/20 0.40
H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P62805 1/20 0.40
APP P05067 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2817725 0.86 LMNA (0.48) ADORA1MAPK8ADORA3MEN1KMT2A
SCHEMBL2816804 0.86 MAPK8 (0.60) ADORA1MAPK8ADORA3MEN1KMT2A
SCHEMBL2820359 0.83 ADORA3 (0.52) IKBKBCHUKADORA1MAPK8ADORA3
SCHEMBL2815566 0.81 HTR2C (0.51) HTR2CIKBKBCHUKTOP2AMEN1
SCHEMBL2816226 0.81 TLR7 (0.48) ADORA1ADORA3MEN1PKMKMT2A
SCHEMBL2818033 0.81 TYMS (0.47) ADORA1MAPK8ADORA3MEN1PKM
SCHEMBL31047843 0.81 TLR7 (0.48) ADORA1ADORA3MEN1PKMKMT2A
SCHEMBL2817490 0.80 MEN1 (0.44) IKBKBADORA1ADORA3MEN1PKM
SCHEMBL2815865 0.80 MEN1 (0.41) MEN1PKMKMT2A
SCHEMBL12440249 0.79 HTR2C (0.49) HTR2CIKBKBCHUKTOP2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS HTR2C 1292/4885IKBKB 855/4885CHUK 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.